- The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication2018 | Central Library of Charles University
- Bcl-2 prevents nitric oxide-mediated apoptosis and poly (ADP-ribose) polymerase clevage.1998 | Faculty of Physical Education and Sport
- Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment2021 | First Faculty of Medicine
- Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment2020 | Publication without faculty affiliation
- Olaparib as a maintenance therapy in newly diagnosed patients with ovarian cancer - SOLO1 study results2022 | Third Faculty of Medicine
- Parp1 hyperactivity couples DNA breaks to aberrant neuronal calcium signalling and lethal seizures2021 | Central Library of Charles University
- Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial2022 | First Faculty of Medicine
- Nové možnosti léčby pacientek s mutacemi genů BRCA1/2 a karcinomem ovarií2017 | First Faculty of Medicine
- Benefit of olaparib in the treatment of ovarian cancer – clinical practice2023 | Third Faculty of Medicine
- The use of niraparib in the treatment of ovarian cancer2023 | First Faculty of Medicine
- Platinum-sensitive recurrent ovarian cancer and olaparib maintenance treatment - case report2019 | First Faculty of Medicine
- Niraparib expands the availability of maintenance therapy in patients with advanced high-grade ovarian cancer2022 | Faculty of Medicine in Pilsen
- PARP inhibitors in treating metastatic castration-resistant prostate cancer2023 | First Faculty of Medicine
- Treatment strategy of triple negative breast cancer in young women - do we treat them differently?2023 | First Faculty of Medicine
- Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)2021 | Publication without faculty affiliation
- Novel modified leucine and phenylalanine dipeptides modulate viability and attachment of cancer cells2020 | Faculty of Science
- WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors2019 | Central Library of Charles University
- Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C32020 | Faculty of Pharmacy in Hradec Králové
- CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells2017 | Second Faculty of Medicine
- The SC-35 Splicing Factor Interacts with RNA Pol II and A-Type Lamin Depletion Weakens This Interaction2021 | First Faculty of Medicine
- Genetic testing in ovarian cancer2022 | First Faculty of Medicine
- Sensitivity of cells to apoptosis induced by iron deprivation can be reversibly changed by iron availability2006 | Central Library of Charles University, Third Faculty of Medicine
- Testing of mutations in BRCA1 and BECA2 genes in tumor tissues - possibilities and limitations2016 | Faculty of Medicine in Hradec Králové
- BRCA1 and BRCA2 - pathologist's starting kit2016 | Second Faculty of Medicine
- European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancerPublication without faculty affiliation
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerPublication without faculty affiliation